2020 Fibromyalgia Drug Pipeline Report- Current Status, Phase, Mechanism, Route of Administration, and Companies, of Pre-Clinical And Clinical Drugs
The 2020 Fibromyalgia pipeline report presents a comprehensive overview of the research and development of Fibromyalgia drug candidates. It presents drugs in development that could potentially reach the market in the next 5 to 10 years: Two drugs in Phase 3, six drugs in Phase 2, three drugs in Phase 1 and 4 drugs in pre-clinical phase
As of February 2020, the Fibromyalgia pipeline remains robust with 15 therapeutic candidates under development. An increasing number of companies are actively participating in the development of Fibromyalgia treatment. Diverse types of targeted therapies are being explored through clinical trials including Cannabinoid receptor agonist; Cannabinoid receptor CB1 antagonist; Cannabinoid receptor CB2 antagonist; Cyclooxygenase 2 inhibitor; NMDA receptor agonist; mu-opioid receptor agonist; Adrenergic uptake inhibitor; Serotonin uptake inhibitor; CACNA2D1 protein modulators; Histamine H1 receptor antagonist; Serotonin 2A receptor antagonist; Alpha 1 adrenergic receptor antagonist.
The report provides complete details of pipeline drugs including the development phase, mechanism of action, companies involved, clinical trial developments, molecule type, and other details. Further, the report also provides Fibromyalgia drug development history, latest news, and other developments.
It assists companies, governments, investors and research organizations to understand the current status in 2020 and possible development in the next 10 years. Further, it enables readers to track new companies in the market and their developments. The product portfolio of different companies and their growth strategies are also detailed in the report.
PUBLISHER EXPERTISE
VPAResearch online databases analyze pipeline drugs and developments for over 2,000 diseases worldwide. All our reports and databases are developed through intensive primary and secondary research methods. The insights and data presented in the databases are validated through industry experts and represent completely unbiased opinions.
SCOPE:
Fibromyalgia pipeline drugs profiled in the report include- IMC-1 (celecoxib + famciclovir), NYX-2925, ASP0819, IRT-103 LODONAL (naltrexone), Palmitoylethanolamide, GRT9906, AP-CBD/THC (Cannabidiol/tetrahydrocannabinol), Pregabalin sustained release, LY03012, NP013, Oral Disintegrating Tablet for Fibromyalgia and chronic pain syndromes, PPP001, fremanezumab, TNX-102, VB210
As of February 2020, the Fibromyalgia pipeline remains robust with 15 therapeutic candidates under development. An increasing number of companies are actively participating in the development of Fibromyalgia treatment. Diverse types of targeted therapies are being explored through clinical trials including Cannabinoid receptor agonist; Cannabinoid receptor CB1 antagonist; Cannabinoid receptor CB2 antagonist; Cyclooxygenase 2 inhibitor; NMDA receptor agonist; mu-opioid receptor agonist; Adrenergic uptake inhibitor; Serotonin uptake inhibitor; CACNA2D1 protein modulators; Histamine H1 receptor antagonist; Serotonin 2A receptor antagonist; Alpha 1 adrenergic receptor antagonist.
The report provides complete details of pipeline drugs including the development phase, mechanism of action, companies involved, clinical trial developments, molecule type, and other details. Further, the report also provides Fibromyalgia drug development history, latest news, and other developments.
It assists companies, governments, investors and research organizations to understand the current status in 2020 and possible development in the next 10 years. Further, it enables readers to track new companies in the market and their developments. The product portfolio of different companies and their growth strategies are also detailed in the report.
PUBLISHER EXPERTISE
VPAResearch online databases analyze pipeline drugs and developments for over 2,000 diseases worldwide. All our reports and databases are developed through intensive primary and secondary research methods. The insights and data presented in the databases are validated through industry experts and represent completely unbiased opinions.
SCOPE:
- The report scope comprises of both pre-clinical phase and clinical phase development drugs for Fibromyalgia development
- Fibromyalgia pipeline compounds and molecules under study by both large scale and small companies are included in the report
- Fibromyalgia pipeline across different phases including discovery, research, and pre-clinical stage, phase 1, phase 2, phase 3 and pre-registration phases are covered
- Drug profile comprising of current development status, regulatory progress, companies, sponsors, mechanism of action, route of administration, molecule, and discovery details are covered
- Further, orphan drug status, fast track designation, different grants awarded and special status for Fibromyalgia pipeline candidates included
- Business overview and snapshot of all companies involved in Fibromyalgia pipeline are included
- Latest market and pipeline developments are provided in the report
Fibromyalgia pipeline drugs profiled in the report include- IMC-1 (celecoxib + famciclovir), NYX-2925, ASP0819, IRT-103 LODONAL (naltrexone), Palmitoylethanolamide, GRT9906, AP-CBD/THC (Cannabidiol/tetrahydrocannabinol), Pregabalin sustained release, LY03012, NP013, Oral Disintegrating Tablet for Fibromyalgia and chronic pain syndromes, PPP001, fremanezumab, TNX-102, VB210
1. TABLE OF CONTENTS
1.1 List of Tables
1.2 List of Figures
2. EXECUTIVE SUMMARY
2.1 Report Scope and Research Methodology
2.2 Introduction to Fibromyalgia Condition
2.3 Fibromyalgia Pipeline Snapshot, 2020
2.4 Companies investing in Fibromyalgia pipeline therapeutics
2.5 Phase wise Fibromyalgia Pipeline Candidates
2.6 Most Researched Mechanism of Action of Fibromyalgia Pipeline Products
2.7 Route of Administration of Fibromyalgia Pipeline Drugs
3. COMPANIES ACTIVE IN PIPELINE DEVELOPMENT
3.1 Aptinyx Inc Overview, Contacts and ASD Pipeline Drugs
3.2 Astellas Pharma Inc Overview, Contacts and ASD Pipeline Drugs
3.3 Cytocom Inc Overview, Contacts and ASD Pipeline Drugs
3.4 FSD Pharma Inc Overview, Contacts and ASD Pipeline Drugs
3.5 Grunenthal GmbH Overview, Contacts and ASD Pipeline Drugs
3.6 Innovative Med Concepts LLC Overview, Contacts and ASD Pipeline Drugs
3.7 Intec Pharma Ltd Overview, Contacts and ASD Pipeline Drugs
3.8 Jiangsu Hengrui Medicine Co Ltd Overview, Contacts and ASD Pipeline Drugs
3.9 Luye Pharma Group Ltd Overview, Contacts and ASD Pipeline Drugs
3.10 One World Cannabis Ltd Overview, Contacts and ASD Pipeline Drugs
3.11 Tetra Bio-Pharma Inc Overview, Contacts and ASD Pipeline Drugs
3.12 Teva Pharmaceutical Industries Ltd Overview, Contacts and ASD Pipeline Drugs
3.13 Tonix Pharmaceuticals Holding Corp Overview, Contacts and ASD Pipeline Drugs
3.14 Vitality Biopharma Inc Overview, Contacts and ASD Pipeline Drugs
4. ACTIVE PIPELINE DRUG DETAILS, 2020
4.1 IMC-1 (celecoxib + famciclovir) Drug Details
4.1.1 IMC-1 (celecoxib + famciclovir) Current Status
4.1.2 IMC-1 (celecoxib + famciclovir) Drug Overview
4.1.3 IMC-1 (celecoxib + famciclovir) Mechanism of Action
4.1.4 IMC-1 (celecoxib + famciclovir) Licensing/Collaboration Companies
4.1.5 IMC-1 (celecoxib + famciclovir) Clinical Trials
4.2 NYX-2925 Drug Details
4.2.1 NYX-2925 Current Status
4.2.2 NYX-2925 Drug Overview
4.2.3 NYX-2925 Mechanism of Action
4.2.4 NYX-2925 Licensing/Collaboration Companies
4.2.5 NYX-2925 Clinical Trials
4.3 ASP0819 Drug Details
4.3.1 ASP0819 Current Status
4.3.2 ASP0819 Drug Overview
4.3.3 ASP0819 Mechanism of Action
4.3.4 ASP0819 Licensing/Collaboration Companies
4.3.5 ASP0819 Clinical Trials
4.4 IRT-103 LODONAL (naltrexone) Drug Details
4.4.1 IRT-103 LODONAL (naltrexone) Current Status
4.4.2 IRT-103 LODONAL (naltrexone) Drug Overview
4.4.3 IRT-103 LODONAL (naltrexone) Mechanism of Action
4.4.4 IRT-103 LODONAL (naltrexone) Licensing/Collaboration Companies
4.4.5 IRT-103 LODONAL (naltrexone) Clinical Trials
4.5 Palmitoylethanolamide Drug Details
4.5.1 Palmitoylethanolamide Current Status
4.5.2 Palmitoylethanolamide Drug Overview
4.5.3 Palmitoylethanolamide Mechanism of Action
4.5.4 Palmitoylethanolamide Licensing/Collaboration Companies
4.5.5 Palmitoylethanolamide Clinical Trials
4.6 GRT9906 Drug Details
4.6.1 GRT9906 Current Status
4.6.2 GRT9906 Drug Overview
4.6.3 GRT9906 Mechanism of Action
4.6.4 GRT9906 Licensing/Collaboration Companies
4.6.5 GRT9906 Clinical Trials
4.7 AP-CBD/THC (Cannabidiol/tetrahydrocannabinol) Drug Details
4.7.1 AP-CBD/THC (Cannabidiol/tetrahydrocannabinol) Current Status
4.7.2 AP-CBD/THC (Cannabidiol/tetrahydrocannabinol) Drug Overview
4.7.3 AP-CBD/THC (Cannabidiol/tetrahydrocannabinol) Mechanism of Action
4.7.4 AP-CBD/THC (Cannabidiol/tetrahydrocannabinol) Licensing/Collaboration Companies
4.7.5 AP-CBD/THC (Cannabidiol/tetrahydrocannabinol) Clinical Trials
4.8 Pregabalin sustained release Drug Details
4.8.1 Pregabalin sustained release Current Status
4.8.2 Pregabalin sustained release Drug Overview
4.8.3 Pregabalin sustained release Mechanism of Action
4.8.4 Pregabalin sustained release Licensing/Collaboration Companies
4.8.5 Pregabalin sustained release Clinical Trials
4.9 LY03012 Drug Details
4.9.1 LY03012 Current Status
4.9.2 LY03012 Drug Overview
4.9.3 LY03012 Mechanism of Action
4.9.4 LY03012 Licensing/Collaboration Companies
4.9.5 LY03012 Clinical Trials
4.10 NP013 Drug Details
4.10.1 NP013 Current Status
4.10.2 NP013 Drug Overview
4.10.3 NP013 Mechanism of Action
4.10.4 NP013 Licensing/Collaboration Companies
4.10.5 NP013 Clinical Trials
4.11 Oral Disintegrating Tablet Fibromyalgia and chronic pain syndromes Drug Details
4.11.1 Oral Disintegrating Tablet Fibromyalgia and chronic pain syndromes Current Status
4.11.2 Oral Disintegrating Tablet Fibromyalgia and chronic pain syndromes Drug Overview
4.11.3 Oral Disintegrating Tablet Fibromyalgia and chronic pain syndromes Mechanism of Action
4.11.4 Oral Disintegrating Tablet Fibromyalgia and chronic pain syndromes Licensing/Collaboration Companies
4.11.5 Oral Disintegrating Tablet Fibromyalgia and chronic pain syndromes Clinical Trials
4.12 PPP001 Drug Details
4.12.1 PPP001 Current Status
4.12.2 PPP001 Drug Overview
4.12.3 PPP001 Mechanism of Action
4.12.4 PPP001 Licensing/Collaboration Companies
4.12.5 PPP001 Clinical Trials
4.13 fremanezumab Drug Details
4.13.1 fremanezumab Current Status
4.13.2 fremanezumab Drug Overview
4.13.3 fremanezumab Mechanism of Action
4.13.4 fremanezumab Licensing/Collaboration Companies
4.13.5 fremanezumab Clinical Trials
4.14 TNX-102 Drug Details
4.14.1 TNX-102 Current Status
4.14.2 TNX-102 Drug Overview
4.14.3 TNX-102 Mechanism of Action
4.14.4 TNX-102 Licensing/Collaboration Companies
4.14.5 TNX-102 Clinical Trials
4.15 VB210 Drug Details
4.15.1 VB210 Current Status
4.15.2 VB210 Drug Overview
4.15.3 VB210 Mechanism of Action
4.15.4 VB210 Licensing/Collaboration Companies
4.15.5 VB210 Clinical Trials
5. LATEST FIBROMYALGIA PIPELINE NEWS AND DEALS
6. APPENDIX
6.1 Our Databases and Reports
6.2 Research Methodolgy
1.1 List of Tables
1.2 List of Figures
2. EXECUTIVE SUMMARY
2.1 Report Scope and Research Methodology
2.2 Introduction to Fibromyalgia Condition
2.3 Fibromyalgia Pipeline Snapshot, 2020
2.4 Companies investing in Fibromyalgia pipeline therapeutics
2.5 Phase wise Fibromyalgia Pipeline Candidates
2.6 Most Researched Mechanism of Action of Fibromyalgia Pipeline Products
2.7 Route of Administration of Fibromyalgia Pipeline Drugs
3. COMPANIES ACTIVE IN PIPELINE DEVELOPMENT
3.1 Aptinyx Inc Overview, Contacts and ASD Pipeline Drugs
3.2 Astellas Pharma Inc Overview, Contacts and ASD Pipeline Drugs
3.3 Cytocom Inc Overview, Contacts and ASD Pipeline Drugs
3.4 FSD Pharma Inc Overview, Contacts and ASD Pipeline Drugs
3.5 Grunenthal GmbH Overview, Contacts and ASD Pipeline Drugs
3.6 Innovative Med Concepts LLC Overview, Contacts and ASD Pipeline Drugs
3.7 Intec Pharma Ltd Overview, Contacts and ASD Pipeline Drugs
3.8 Jiangsu Hengrui Medicine Co Ltd Overview, Contacts and ASD Pipeline Drugs
3.9 Luye Pharma Group Ltd Overview, Contacts and ASD Pipeline Drugs
3.10 One World Cannabis Ltd Overview, Contacts and ASD Pipeline Drugs
3.11 Tetra Bio-Pharma Inc Overview, Contacts and ASD Pipeline Drugs
3.12 Teva Pharmaceutical Industries Ltd Overview, Contacts and ASD Pipeline Drugs
3.13 Tonix Pharmaceuticals Holding Corp Overview, Contacts and ASD Pipeline Drugs
3.14 Vitality Biopharma Inc Overview, Contacts and ASD Pipeline Drugs
4. ACTIVE PIPELINE DRUG DETAILS, 2020
4.1 IMC-1 (celecoxib + famciclovir) Drug Details
4.1.1 IMC-1 (celecoxib + famciclovir) Current Status
4.1.2 IMC-1 (celecoxib + famciclovir) Drug Overview
4.1.3 IMC-1 (celecoxib + famciclovir) Mechanism of Action
4.1.4 IMC-1 (celecoxib + famciclovir) Licensing/Collaboration Companies
4.1.5 IMC-1 (celecoxib + famciclovir) Clinical Trials
4.2 NYX-2925 Drug Details
4.2.1 NYX-2925 Current Status
4.2.2 NYX-2925 Drug Overview
4.2.3 NYX-2925 Mechanism of Action
4.2.4 NYX-2925 Licensing/Collaboration Companies
4.2.5 NYX-2925 Clinical Trials
4.3 ASP0819 Drug Details
4.3.1 ASP0819 Current Status
4.3.2 ASP0819 Drug Overview
4.3.3 ASP0819 Mechanism of Action
4.3.4 ASP0819 Licensing/Collaboration Companies
4.3.5 ASP0819 Clinical Trials
4.4 IRT-103 LODONAL (naltrexone) Drug Details
4.4.1 IRT-103 LODONAL (naltrexone) Current Status
4.4.2 IRT-103 LODONAL (naltrexone) Drug Overview
4.4.3 IRT-103 LODONAL (naltrexone) Mechanism of Action
4.4.4 IRT-103 LODONAL (naltrexone) Licensing/Collaboration Companies
4.4.5 IRT-103 LODONAL (naltrexone) Clinical Trials
4.5 Palmitoylethanolamide Drug Details
4.5.1 Palmitoylethanolamide Current Status
4.5.2 Palmitoylethanolamide Drug Overview
4.5.3 Palmitoylethanolamide Mechanism of Action
4.5.4 Palmitoylethanolamide Licensing/Collaboration Companies
4.5.5 Palmitoylethanolamide Clinical Trials
4.6 GRT9906 Drug Details
4.6.1 GRT9906 Current Status
4.6.2 GRT9906 Drug Overview
4.6.3 GRT9906 Mechanism of Action
4.6.4 GRT9906 Licensing/Collaboration Companies
4.6.5 GRT9906 Clinical Trials
4.7 AP-CBD/THC (Cannabidiol/tetrahydrocannabinol) Drug Details
4.7.1 AP-CBD/THC (Cannabidiol/tetrahydrocannabinol) Current Status
4.7.2 AP-CBD/THC (Cannabidiol/tetrahydrocannabinol) Drug Overview
4.7.3 AP-CBD/THC (Cannabidiol/tetrahydrocannabinol) Mechanism of Action
4.7.4 AP-CBD/THC (Cannabidiol/tetrahydrocannabinol) Licensing/Collaboration Companies
4.7.5 AP-CBD/THC (Cannabidiol/tetrahydrocannabinol) Clinical Trials
4.8 Pregabalin sustained release Drug Details
4.8.1 Pregabalin sustained release Current Status
4.8.2 Pregabalin sustained release Drug Overview
4.8.3 Pregabalin sustained release Mechanism of Action
4.8.4 Pregabalin sustained release Licensing/Collaboration Companies
4.8.5 Pregabalin sustained release Clinical Trials
4.9 LY03012 Drug Details
4.9.1 LY03012 Current Status
4.9.2 LY03012 Drug Overview
4.9.3 LY03012 Mechanism of Action
4.9.4 LY03012 Licensing/Collaboration Companies
4.9.5 LY03012 Clinical Trials
4.10 NP013 Drug Details
4.10.1 NP013 Current Status
4.10.2 NP013 Drug Overview
4.10.3 NP013 Mechanism of Action
4.10.4 NP013 Licensing/Collaboration Companies
4.10.5 NP013 Clinical Trials
4.11 Oral Disintegrating Tablet Fibromyalgia and chronic pain syndromes Drug Details
4.11.1 Oral Disintegrating Tablet Fibromyalgia and chronic pain syndromes Current Status
4.11.2 Oral Disintegrating Tablet Fibromyalgia and chronic pain syndromes Drug Overview
4.11.3 Oral Disintegrating Tablet Fibromyalgia and chronic pain syndromes Mechanism of Action
4.11.4 Oral Disintegrating Tablet Fibromyalgia and chronic pain syndromes Licensing/Collaboration Companies
4.11.5 Oral Disintegrating Tablet Fibromyalgia and chronic pain syndromes Clinical Trials
4.12 PPP001 Drug Details
4.12.1 PPP001 Current Status
4.12.2 PPP001 Drug Overview
4.12.3 PPP001 Mechanism of Action
4.12.4 PPP001 Licensing/Collaboration Companies
4.12.5 PPP001 Clinical Trials
4.13 fremanezumab Drug Details
4.13.1 fremanezumab Current Status
4.13.2 fremanezumab Drug Overview
4.13.3 fremanezumab Mechanism of Action
4.13.4 fremanezumab Licensing/Collaboration Companies
4.13.5 fremanezumab Clinical Trials
4.14 TNX-102 Drug Details
4.14.1 TNX-102 Current Status
4.14.2 TNX-102 Drug Overview
4.14.3 TNX-102 Mechanism of Action
4.14.4 TNX-102 Licensing/Collaboration Companies
4.14.5 TNX-102 Clinical Trials
4.15 VB210 Drug Details
4.15.1 VB210 Current Status
4.15.2 VB210 Drug Overview
4.15.3 VB210 Mechanism of Action
4.15.4 VB210 Licensing/Collaboration Companies
4.15.5 VB210 Clinical Trials
5. LATEST FIBROMYALGIA PIPELINE NEWS AND DEALS
6. APPENDIX
6.1 Our Databases and Reports
6.2 Research Methodolgy
